Deep Track Capital, LP
Deep Track Capital, LP reported 66 US-listed holdings worth $6.79 billion in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Guardant Health Inc. (7.5%), Immunovant Inc. (5.3%) and Structure Therapeutics Inc. (3.7%). Against the quarter before, it opened 18 positions, added to 21, trimmed 15 and sold out of 14.
Reported holdings$6.79B+40.1% on Q1 2026
Positions66+4 on Q1 2026
The largest ten40.1%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
OpenedAdded toHeldTrimmed
The 14 largest of its 66 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What it did on the quarter
Opened 18Added 21Held 12Trimmed 15Sold out 14
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 18
- Alnylam Pharmaceuticals Inc ALNY$248.3 million
- Hemab Therapeutics Hldgs Inc. COAG$132.3 million
- GH Research PLC GHRS$89.6 million
- United Therapeutics Corp. UTHR$67.0 million
- Avalo Therapeutics Inc. AVTX$66.7 million
- Altimmune, Inc. (alt) ALT$58.5 million
- Genedx Holdings Corp. WGS$48.1 million
- Harrow Inc. HROW$41.2 million
and 10 more in the table below
Added to 21
- Veradermics Inc MANE+1.5 million shares · +300%
- Biomarin Pharmaceutical Inc. BMRN+2.2 million shares · +188%
- Celldex Therapeutics Inc. CLDX+1.7 million shares · +129%
- Genmab A/S GMAB+2.0 million shares · +54%
- Nuvalent Inc. NUVL+406,998 shares · +30%
- Tango Therapeutics Inc. TNGX+1.4 million shares · +53%
- Viridian Therapeutics Inc. VRDN+2.2 million shares · +158%
- Cogent Biosciences Inc. COGT+1.0 million shares · +100%
and 13 more in the table below
Trimmed 15
- Axsome Therapeutics Inc. AXSM-400,000 shares · -36%
- Immunovant Inc. IMVT-2.2 million shares · -19%
- Cytokinetics Inc. CYTK-674,320 shares · -49%
- MBX Biosciences Inc. MBX-1.0 million shares · -37%
- Immunocore Hldgs PLC IMCR-1.6 million shares · -84%
- Alumis Inc. ALMS-424,037 shares · -6%
- Definium Therapeutics Inc. DFTX-250,000 shares · -8%
- Dyne Therapeutics Inc. DYN-500,000 shares · -25%
and 7 more in the table below
Sold out of 14
- Apellis Pharmaceuticals Inc. APLS$182.3 million last quarter
- Centessa Pharmaceuticals PLC CNTA$125.4 million last quarter
- Bridgebio Pharma Inc. BBIO$62.5 million last quarter
- Terns Pharmaceuticals Inc. TERN$56.6 million last quarter
- Geron Corp. GERN$47.3 million last quarter
- ANI Pharmaceuticals Inc. ANIP$46.1 million last quarter
- Soleno Therapeutics Inc. SLNO$36.1 million last quarter
- Engene Holdings Inc. ENGN$29.8 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Guardant Health Inc. GH | 3,393,312 | $509.1 million | 7.50% | +55,071 |
| Immunovant Inc. IMVT | 9,341,151 | $359.9 million | 5.30% | -2,185,820 |
| Structure Therapeutics Inc. GPCR | 4,740,072 | $254.4 million | 3.75% | +460,224 |
| Vaxcyte Inc. PCVX | 4,300,000 | $250.0 million | 3.68% | no change |
| Alnylam Pharmaceuticals Inc ALNY | 825,000 | $248.3 million | 3.66% | new |
| Veradermics Inc MANE | 2,000,000 | $245.9 million | 3.62% | +1,500,000 |
| Tarsus Pharmaceuticals Inc. TARS | 3,666,768 | $230.8 million | 3.40% | +66,768 |
| Nuvalent Inc. NUVL | 1,783,322 | $220.2 million | 3.24% | +406,998 |
| Alkermes plc. ALKS | 4,000,000 | $209.6 million | 3.09% | +409,677 |
| Ocular Therapeutix Inc. OCUL | 19,686,282 | $193.3 million | 2.85% | no change |
| Biomarin Pharmaceutical Inc. BMRN | 3,307,481 | $189.3 million | 2.79% | +2,157,481 |
| Nurix Therapeutics Inc. NRIX | 7,736,455 | $187.7 million | 2.76% | +1,391,211 |
| Oruka Therapeutics Inc. ORKA | 1,926,000 | $183.3 million | 2.70% | -108,203 |
| Alumis Inc. ALMS | 6,348,558 | $178.6 million | 2.63% | -424,037 |
| Ionis Pharmaceuticals Inc. IONS | 2,200,000 | $174.4 million | 2.57% | +250,000 |
| Compass Pathways PLC CMPS | 12,161,496 | $172.1 million | 2.54% | no change |
| Vera Therapeutics Inc. VERA | 4,000,000 | $171.6 million | 2.53% | -106,067 |
| Axsome Therapeutics Inc. AXSM | 700,000 | $171.3 million | 2.52% | -400,000 |
| Genmab A/S GMAB | 5,650,000 | $155.2 million | 2.29% | +1,986,750 |
| Moonlake Immunotherapeutics MLTX | 6,999,025 | $136.3 million | 2.01% | +590,162 |
| Hemab Therapeutics Hldgs Inc. COAG | 3,602,093 | $132.3 million | 1.95% | new |
| Tango Therapeutics Inc. TNGX | 4,200,000 | $131.3 million | 1.93% | +1,450,000 |
| Definium Therapeutics Inc. DFTX | 2,750,000 | $129.4 million | 1.91% | -250,000 |
| Grail, Inc. GRAL | 1,834,944 | $125.3 million | 1.85% | +112,147 |
| Bicara Therapeutics Inc. BCAX | 4,100,000 | $121.7 million | 1.79% | +37,500 |
| Maze Therapeatics MAZE | 3,732,569 | $111.4 million | 1.64% | +255,007 |
| Celldex Therapeutics Inc. CLDX | 2,939,151 | $109.4 million | 1.61% | +1,655,172 |
| LB Pharmaceuticals Inc. LBRX | 3,352,804 | $108.8 million | 1.60% | no change |
| MBX Biosciences Inc. MBX | 1,732,569 | $95.6 million | 1.41% | -1,025,000 |
| GH Research PLC GHRS | 3,333,334 | $89.6 million | 1.32% | new |
| Cogent Biosciences Inc. COGT | 2,000,000 | $77.4 million | 1.14% | +1,000,000 |
| Atai Beckley NV ATAI | 14,417,442 | $76.0 million | 1.12% | +2,417,442 |
| United Therapeutics Corp. UTHR | 123,616 | $67.0 million | 0.99% | new |
| Avalo Therapeutics Inc. AVTX | 3,610,000 | $66.7 million | 0.98% | new |
| Viridian Therapeutics Inc. VRDN | 3,592,740 | $66.0 million | 0.97% | +2,198,796 |
| Cytokinetics Inc. CYTK | 700,000 | $59.6 million | 0.88% | -674,320 |
| Altimmune, Inc. (alt) ALT | 19,250,000 | $58.5 million | 0.86% | new |
| Personalis Inc. PSNL | 4,000,000 | $53.6 million | 0.79% | +1,000,000 |
| Aclaris Therapeutics Inc. ACRS | 9,345,000 | $49.4 million | 0.73% | no change |
| Cormedix Inc. CRMD | 6,274,076 | $49.3 million | 0.73% | no change |
| Genedx Holdings Corp. WGS | 700,000 | $48.1 million | 0.71% | new |
| Harrow Inc. HROW | 969,000 | $41.2 million | 0.61% | new |
| Corvus Pharmaceuticals Inc. CRVS | 2,491,939 | $37.2 million | 0.55% | +400 |
| Solid Biosciences Inc. SLDB | 3,565,062 | $35.6 million | 0.52% | no change |
| Beam Therapeutics Inc. BEAM | 1,000,000 | $34.3 million | 0.51% | +179,235 |
| Dyne Therapeutics Inc. DYN | 1,500,000 | $33.3 million | 0.49% | -500,000 |
| Immix Biopharma Inc. IMMX | 2,775,000 | $28.6 million | 0.42% | new |
| X4 Pharmaceuticals Inc. XFOR | 5,878,757 | $27.5 million | 0.40% | -460,778 |
| Shattuck Labs Inc. STTK | 3,706,734 | $25.7 million | 0.38% | new |
| Mannkind Corp. MNKD | 6,000,000 | $25.6 million | 0.38% | new |
| Century Therapeutics Inc. IPSC | 9,462,645 | $23.2 million | 0.34% | -25,100 |
| Generate Biomedicines Inc. GENB | 1,333,815 | $22.5 million | 0.33% | new |
| Verastem Inc. VSTM | 5,740,850 | $21.9 million | 0.32% | no change |
| Kura Oncology Inc. KURA | 1,978,565 | $21.7 million | 0.32% | -664,977 |
| Enanta Pharmaceuticals Inc. ENTA | 1,444,167 | $21.1 million | 0.31% | -512,700 |
| Nektar Therapeutics NKTR | 300,000 | $20.9 million | 0.31% | new |
| Olema Pharmaceuticals Inc. OLMA | 1,500,000 | $18.8 million | 0.28% | new |
| Kailera Therapeutics Inc. KLRA | 700,000 | $15.4 million | 0.23% | new |
| Kardigan Inc. KARD | 600,000 | $14.3 million | 0.21% | new |
| Enliven Therapeutics Inc. ELVN | 225,000 | $11.4 million | 0.17% | new |
| Promis Neurosciences Inc. PMN | 835,655 | $11.0 million | 0.16% | no change |
| Immunocore Hldgs PLC IMCR | 311,218 | $9.9 million | 0.15% | -1,620,666 |
| Xencor Inc. XNCR | 593,551 | $9.6 million | 0.14% | new |
| Context Therapeutics Inc. CNTX | 7,419,355 | $4.1 million | 0.06% | no change |
| Inventiva SA IVA | 800,000 | $3.0 million | 0.04% | -422,453 |
| Aligos Therapeutics Inc. ALGS | 444,110 | $2.6 million | 0.04% | no change |
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read more
Change is shares against its 13F for the quarter before; the 14 it sold out of are in the box above.Options it reported
| Company | Option | Shares under the options | Value of those shares |
|---|---|---|---|
| Genmab A/S GMAB | Calls | 3,000,000 | $82.4 million |
1 option lines. A 13F lists calls and puts by the shares they cover and what those shares were worth at the quarter's end, not what the options cost; they are not counted in the holdings above.